MAIA Biotechnology, Inc. reported details about patient survival results from their ongoing Phase 2 clinical trial for non-small cell lung cancer in a press release on October 23, 2025, coinciding with presentations at the ESMO Congress on October 19, 2025. This included posters on two trials, THIO-101 and THIO-104, which were also posted on their website.